Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability

NeuroImage ◽  
2007 ◽  
Vol 37 (1) ◽  
pp. 253-261 ◽  
Author(s):  
Z. Khaleeli ◽  
M. Cercignani ◽  
B. Audoin ◽  
O. Ciccarelli ◽  
D.H. Miller ◽  
...  
2007 ◽  
Vol 64 (3) ◽  
pp. 411 ◽  
Author(s):  
Francesco Manfredonia ◽  
Olga Ciccarelli ◽  
Zhaleh Khaleeli ◽  
Daniel J. Tozer ◽  
Jaume Sastre-Garriga ◽  
...  

2003 ◽  
Vol 250 (1) ◽  
pp. 67-74 ◽  
Author(s):  
J. Dehmeshki ◽  
D. T. Chard ◽  
S. M. Leary ◽  
H. C. Watt ◽  
N. C. Silver ◽  
...  

2018 ◽  
Vol 56 (7) ◽  
pp. 80-84

▼Ocrelizumab (Ocrevus - Roche Registration GmbH) has received marketing authorisation approval from the European Medicines Agency (EMA) for the treatment of adults with multiple sclerosis.1,2 It is the first drug to be licensed for use in early primary progressive multiple sclerosis and relapsing forms of multiple sclerosis. Here, we review the evidence for the safety and effectiveness of ocrelizumab.


NeuroImage ◽  
2014 ◽  
Vol 86 ◽  
pp. 257-264 ◽  
Author(s):  
Arman Eshaghi ◽  
Benedetta Bodini ◽  
Gerard R. Ridgway ◽  
Daniel García-Lorenzo ◽  
Daniel J. Tozer ◽  
...  

Brain ◽  
2005 ◽  
Vol 128 (6) ◽  
pp. 1454-1460 ◽  
Author(s):  
Jaume Sastre-Garriga ◽  
Gordon T. Ingle ◽  
Declan T. Chard ◽  
Mara Cercignani ◽  
Lluís Ramió-Torrentà ◽  
...  

2006 ◽  
Vol 63 (8) ◽  
pp. 1175 ◽  
Author(s):  
Jorge Sepulcre ◽  
Jaume Sastre-Garriga ◽  
Mara Cercignani ◽  
Gordon T. Ingle ◽  
David H. Miller ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document